Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Active, not recruiting · NCT03989089 · Registry updated 2024-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation | HER2-Negative Breast Cancer | Active, not recruiting | Phase 2 | 2024-12-18 | NCT03989089 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Research Malaysia | 2 |
| Merck Sharp & Dohme LLC | 650 |
| National University Hospital, Singapore | 120 |
| University of Malaya | 67 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National University Hospital | Singapore | Singapore | 29 |
| University Malaya Medical Centre | Kuala Lumpur | Malaysia | 12 |